@article{ref1,
title="Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK",
journal="Human psychopharmacology",
year="2015",
author="Singer, Lynn T. and Moore, Derek G. and Min, Meeyoung O. and Goodwin, Julia and Turner, John J. D. and Fulton, Sarah and Parrott, Andrew C.",
volume="30",
number="4",
pages="290-294",
abstract="OBJECTIVE: This paper aims to review findings from a longitudinal study of prenatal methylenedioxymethamphetamine (MDMA, &quot;ecstasy&quot;) on infant development. <br><br>METHODS: In a prospective, longitudinal cohort design, we followed 28 MDMA-exposed and 68 non-MDMA-exposed infants from birth to 2 years of age. Women recruited voluntarily into a study of recreational drug use during pregnancy were interviewed to obtain type, frequency, and amount of recreational drug use. Their children were followed for a 2-year period after birth. A large number of drug and environmental covariates were controlled. Infants were seen at 1, 4, 12, 18, and 24 months using standardized normative tests of mental and motor development. <br><br>RESULTS: There were no differences between MDMA-exposed and non-MDMA-exposed infants at birth except that MDMA-exposed infants were more likely to be male. Motor delays were evident in MDMA infants at each age and amount of MDMA exposure predicted motor deficits at 12 months in a dose-dependent fashion. <br><br>CONCLUSIONS: Prenatal MDMA exposure is related to fine and gross motor delays in the first 2 years of life. Follow-up studies are needed to determine long-term effects. Copyright © 2015 John Wiley & Sons, Ltd.<p /> <p>Language: en</p>",
language="en",
issn="0885-6222",
doi="10.1002/hup.2459",
url="http://dx.doi.org/10.1002/hup.2459"
}